# US 2013/0295058 A1 · Pharmaceutical Compositions Comprising Gingiva A-Derived Mesenchymal Stem Cells and Methods of Treating Inflammation, Wound Healing and Contact Hypersensitivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295058 A1
- Document ID: US20130295058A1
- Status: Published application
- Kind: A1
- Application number: 13/809,876
- Filed: 2011-07-14
- Published: 2013-11-07
- Earliest claimed: 2010-07-14
- Assignees: University of Southern California
- Inventors: Anh D. Le; Qunzhou Zhang
- Web page: https://patentgrep.com/patent/US20130295058A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity.

## Claims

### Claim 1

A pharmaceutical composition comprising an effective amount of pharmaceutical composition comprising human gingiva-derived mesenchymal stem cells in a carrier medium.

### Claim 2

A method of promoting (enhancing) cutaneous wound healing comprising:
administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls.

### Claim 3 (depends on 2)

The method of claim 2, wherein said administration results rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls.

### Claim 4 (depends on 2)

The method of claim 2, wherein the administration comprises systemic administration.

### Claim 5 (depends on 2)

The method of claim 2, wherein the administration results in accelerated wound closure.

### Claim 6

An immunomodulatory method of polarizing macrophages to exhibit M2 phenotype, comprising:
introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with said gingiva-derived mesenchymal stem cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein, said macrophages exhibit by at least one of an increased expression of mannose receptor (MR/CD206), increased expression of IL-10 and IL-6, a suppressed production of TNF-α, and decreased ability to induce Th-17 cell expansion relative to a similar population of untreated macrophages.

### Claim 8 (depends on 7)

The method of claim 7, wherein, after introduction, the macrophages are characterized by a suppressed production of TNF-α.

### Claim 9

A method for attenuating contact hypersensitivity comprising:
administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity.

### Claim 10 (depends on 9)

The method of claim 9, wherein the human gingiva-derived mesenchymal stem cells are administered before sensitization.

### Claim 11 (depends on 8)

The method of claim 8, wherein the human gingiva-derived mesenchymal stem cells are administered before challenge.

### Claim 12 (depends on 8)

The method of claim 8, wherein the administration is systemic administration.
